Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
11 2021
Historique:
received: 11 11 2020
revised: 05 04 2021
accepted: 11 06 2021
pubmed: 30 6 2021
medline: 17 3 2022
entrez: 29 6 2021
Statut: ppublish

Résumé

AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted gene sequencing, 152 RNA sequencing, 67 single nucleotide polymorphism arrays), we found a driver role for

Identifiants

pubmed: 34183353
pii: 2159-8290.CD-20-1647
doi: 10.1158/2159-8290.CD-20-1647
pmc: PMC9414283
doi:

Substances chimiques

Biomarkers, Tumor 0
Cell Cycle Proteins 0
MDM4 protein, human 0
Proto-Oncogene Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2796-2811

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : VA
ID : PEC 16-001
Pays : United States

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
Eur J Cancer. 2019 Oct;120:54-64
pubmed: 31491604
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Genomics. 2000 Oct 15;69(2):271-4
pubmed: 11031110
Cancer Res. 2017 May 1;77(9):2213-2221
pubmed: 28249905
Ann Oncol. 2019 Mar 1;30(3):365-373
pubmed: 30715161
Oncologist. 2019 Jul;24(7):893-900
pubmed: 30679318
JAMA Oncol. 2017 Feb 01;3(2):227-234
pubmed: 27684533
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
NPJ Breast Cancer. 2017 Jun 29;3:23
pubmed: 28685159
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
JNCI Cancer Spectr. 2018 Nov;2(4):pky062
pubmed: 30627694
Cancer Treat Rev. 2016 Nov;50:205-207
pubmed: 27744144
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Commun. 2019 Mar 26;10(1):1373
pubmed: 30914635
Cancer Discov. 2020 Jan;10(1):72-85
pubmed: 31594766
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Nat Genet. 2020 Jul;52(7):701-708
pubmed: 32424352
Breast Cancer Res. 2020 Aug 18;22(1):91
pubmed: 32811538
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
Cancer Discov. 2011 Jun;1(1):54-67
pubmed: 22039576
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
N Engl J Med. 2014 Aug 7;371(6):583-4
pubmed: 25099597
Br J Cancer. 2014 Nov 11;111(10):1881-7
pubmed: 25225904
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
Nat Genet. 2019 Oct;51(10):1450-1458
pubmed: 31570896
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Cancer Res. 2021 Jan 1;81(1):77-90
pubmed: 32967925
J Clin Oncol. 2020 Dec 20;38(36):4274-4282
pubmed: 33119476
J Clin Oncol. 2021 May 1;39(13):1458-1467
pubmed: 33769862
Nat Commun. 2020 May 1;11(1):2135
pubmed: 32358509
Oncologist. 2015 May;20(5):474-82
pubmed: 25908555
Nat Med. 2021 Jan;27(1):152-164
pubmed: 33398162
Cancer Cell. 2017 Aug 14;32(2):169-184.e7
pubmed: 28810143
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Oncotarget. 2015 Feb 28;6(6):4345-56
pubmed: 25726523
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
J Clin Invest. 2018 Apr 2;128(4):1371-1383
pubmed: 29480819
Nat Genet. 2019 Dec;51(12):1732-1740
pubmed: 31740835
NPJ Precis Oncol. 2020 Mar 16;4:6
pubmed: 32195359
Nat Genet. 2020 Feb;52(2):198-207
pubmed: 31932695
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346

Auteurs

Philippe Aftimos (P)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.

Mafalda Oliveira (M)

Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Alexandre Irrthum (A)

Breast International Group, Brussels, Belgium.

Debora Fumagalli (D)

Breast International Group, Brussels, Belgium.

Christos Sotiriou (C)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.

Einav Nili Gal-Yam (EN)

Sheba Medical Center, Ramat Gan, Israel.

Mark E Robson (ME)

Memorial Sloan Kettering Cancer Center, New York, New York.

Justin Ndozeng (J)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.

Angelo Di Leo (A)

Hospital of Prato, Prato, Italy.

Eva M Ciruelos (EM)

University Hospital 12 de Octubre, Madrid, Spain.

Evandro de Azambuja (E)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.

Giuseppe Viale (G)

IEO, Istituto Europeo di Oncologia, IRCCS, and University of Milan, Milan, Italy.

Elsemieke D Scheepers (ED)

Frontier Science Scotland, Scotland, United Kingdom.

Giuseppe Curigliano (G)

IEO, Istituto Europeo di Oncologia, IRCCS, and University of Milan, Milan, Italy.

Judith M Bliss (JM)

The Institute of Cancer Research, London, United Kingdom.

Jorge S Reis-Filho (JS)

Hospital of Prato, Prato, Italy.

Marco Colleoni (M)

IEO, Istituto Europeo di Oncologia, IRCCS, and University of Milan, Milan, Italy.

Marija Balic (M)

Medical University of Graz, Graz, Austria.

Fatima Cardoso (F)

Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.

Joan Albanell (J)

Hospital del Mar - CIBERONC; IMIM, Barcelona; Pompeu Fabra University, Barcelona, Spain.

Caroline Duhem (C)

Centre Hospitalier Luxembourg, Luxembourg City, Luxembourg.

Sandrine Marreaud (S)

EORTC, Brussels, Belgium.

Dario Romagnoli (D)

Sheba Medical Center, Ramat Gan, Israel.

Beatriz Rojas (B)

CIOCC (Centro Integral Oncologico "Clara Campal"), Madrid, Spain.

Andrea Gombos (A)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.

Angel Guerrero-Zotano (A)

Instituto Valenciano de Oncología, Valencia, Spain.

Peter Hall (P)

University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.

Andrea Bonetti (A)

Department of Oncology AZIENDA ULSS 9 Verona, Verona, Italy.

Karolina Fs Larsson (KF)

Sahlgrenska University Hospital, Gothenburg, Sweden.

Martina Degiorgis (M)

Centre Hospitalier Luxembourg, Luxembourg City, Luxembourg.

Silvia Khodaverdi (S)

Sana Klinikum Offenbach, Klinik für Gynaekologie und Geburtshilfe, Offenbach, Germany.

Richard Greil (R)

Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria.

Ásgerdur Sverrisdóttir (Á)

Landspitali University Hospital, Reykjavik, Iceland.

Marta Paoli (M)

Sheba Medical Center, Ramat Gan, Israel.

Ethel Seyll (E)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.

Sibylle Loibl (S)

German Breast Group, Neu-Isenburg, Germany.

Barbro Linderholm (B)

Sahlgrenska University Hospital, Gothenburg, Sweden.

Gabriele Zoppoli (G)

Università degli Studi di Genova and IRCCS Ospedale Policlinico San Martino, San Martino, Italy.

Nancy E Davidson (NE)

Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington.

Oskar Th Johannsson (OT)

IBCG, Reykjavik, Iceland.

Philippe L Bedard (PL)

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Sherene Loi (S)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Susan Knox (S)

Europa Donna- The European Breast Cancer Coalition, Milan, Italy.

David A Cameron (DA)

University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.

Nadia Harbeck (N)

Breast Center, LMU University Hospital, Munich, Germany, and West German Study Group, Moenchengladbach, Germany.

Maite Lasa Montoya (ML)

Breast International Group, Brussels, Belgium.

Mariana Brandão (M)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.

Andrea Vingiani (A)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Carmela Caballero (C)

Breast International Group, Brussels, Belgium.

Florentine S Hilbers (FS)

Breast International Group, Brussels, Belgium.

Lucy R Yates (LR)

Wellcome Trust Sanger Institute, London, United Kingdom.

Matteo Benelli (M)

Hospital of Prato, Prato, Italy.

David Venet (D)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.

Martine J Piccart (MJ)

Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium. martine.piccart@bordet.be.
Breast International Group, Brussels, Belgium.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH